These findings identify <i>SFMBT2</i> hypermethylation as a potential noninvasive biomarker for recurrence risk stratification and prognostic assessment in advanced CRC, and suggest a role for <i>SFMBT2</i> in shaping the tumor immune microenvironment. This evidence concerns the gene SFMBT2 and neoplasm.